The first patient has been dosed in a phase 2 trial investigating IBI302 in patients with choroidal neovascularization secondary to wet age-related macular degeneration, according to a press release from Innovent Biologics.
The randomized, double-masked, multicenter, active-controlled trial is investigating IBI302, a “first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bispecific fusion protein,” the release said. The primary outcome of the study will be the efficacy and safety of the therapy.
“IBI302 was designed to provide more targeted treatment and